◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

XILIO THERAPEUTICS, INC.

CIK: 1840233 SIC: 2834
$31.80M
Revenue
$-58.49M
Net Income
-
Gross Margin
-137.64%
Op. Margin
$25.45M
Free Cash Flow
Financial Statements Quarterly (10-Q)
Showing 6 of 13 quarterly reports available
Breakdown Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
+ Total Revenue $19.07M $8.08M $2.93M $1.72M $2.26M $2.36M
Revenue Growth % (YoY) 742.5% 243.0% nan% nan% nan% nan%
Operating Expenses $21.00M $22.45M $16.78M $15.35M $17.02M $17.06M
Research & Development $14.32M $15.33M $8.27M $8.84M $10.76M $11.22M
+ Operating Income $-1.93M $-14.37M $-13.85M $-13.63M $-14.76M $-14.70M
Operating Margin % -10.1% -177.7% -472.7% -790.5% -652.3% -623.8%
Interest Expense - - - - $62.00K $62.00K
Other Income/Expense $1.02M $-1.43M $586.00K $536.00K $742.00K $779.00K
+ Net Income $-16.29M $-15.84M $-13.27M $-13.09M $-14.02M $-13.93M
Net Margin % -85.4% -196.0% -452.7% -759.5% -619.5% -590.8%
Basic EPS -0.11 -0.16 -0.18 -0.18 -0.22 -0.24
Diluted EPS -0.11 -0.16 -0.18 -0.18 -0.22 -0.24
Basic Shares Outstanding 144.1M 96.4M 74.7M 3.7M 63.5M 57.8M
Breakdown Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Cash & Cash Equivalents $103.76M $121.55M $89.07M $55.29M $61.26M $74.95M
Other Current Assets $2.83M $2.17M $4.13M $4.94M $2.05M $3.06M
Total Current Assets $124.09M $123.72M $93.20M $60.23M $63.31M $78.01M
Property Plant & Equipment $3.68M $4.02M $4.29M $4.47M $4.84M $5.14M
Other Non-current Assets - - - - - $92.00K
Total Assets $133.69M $133.81M $103.72M $71.08M $74.66M $89.87M
Accounts Payable $2.30M $4.10M $2.27M $2.57M $972.00K $1.26M
Accrued Liabilities $8.95M $5.62M $3.88M $9.98M $9.79M $9.74M
Deferred Revenue $43.85M $42.28M $40.25M $13.52M $26.11M $26.52M
Other Current Liabilities - - - - - $7.00K
Total Current Liabilities $56.40M $53.26M $47.64M $27.26M $38.02M $38.64M
Total Liabilities $141.79M $126.74M $93.02M $53.48M $53.68M $56.46M
Common Stock $5.00K $5.00K $5.00K $5.00K $4.00K $4.00K
Retained Earnings $-429.15M $-412.86M $-397.02M $-383.75M $-370.66M $-356.64M
Total Stockholders Equity $-8.10M $7.07M $10.70M $17.60M $20.97M $33.42M
Total Liabilities & Equity $133.69M $133.81M $103.72M $71.08M $74.66M $89.87M
Breakdown Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Net Income $-16.29M $-15.84M $-13.27M $-13.09M $-14.02M $-13.93M
Depreciation & Amortization $1.22M $878.00K $497.00K $376.00K $1.27M $888.00K
Stock-based Compensation $4.01M $2.89M $1.53M $1.52M $4.92M $3.34M
Change in Receivables $17.50M - - - - -
Change in Payables $-276.00K $1.52M $-590.00K $1.60M $-76.00K $205.00K
Operating Cash Flow $-2.99M $14.50M $28.98M $-14.16M $-4.22M $9.45M
Capital Expenditure $423.00K $423.00K $22.00K $6.00K $30.00K $21.00K
Investing Cash Flow $-423.00K $-423.00K $-22.00K $-6.00K $-30.00K $-21.00K
Debt Repayment - - - - $3.33M $3.33M
Financing Cash Flow $51.91M $52.19M $4.83M $8.20M $20.99M $21.00M
Net Change in Cash $48.49M $66.27M $33.79M $-5.96M $16.74M $30.43M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Total Revenue $19.07M $2.26M $30.08M $4.62M
Operating Expenses $21.00M $17.02M $60.23M $51.57M
Research & Development $14.32M $10.76M $37.92M $32.38M
Operating Income $-1.93M $-14.76M $-30.15M $-46.95M
Interest Expense - - - $62.00K
Other Income/Expense $1.02M $742.00K $180.00K $1.80M
Net Income $-16.29M $-14.02M $-45.40M $-45.15M
Basic EPS -0.11 -0.22 -0.43 -0.91
Diluted EPS -0.11 -0.22 -0.43 -0.91
Basic Shares Outstanding $144.11M $63.47M $105.34M $49.76M
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $103.76M $55.29M
Other Current Assets $2.83M $4.94M
Total Current Assets $124.09M $60.23M
Property Plant & Equipment $3.68M $4.47M
Total Assets $133.69M $71.08M
Accounts Payable $2.30M $2.57M
Accrued Liabilities $8.95M $9.98M
Deferred Revenue $43.85M $13.52M
Total Current Liabilities $56.40M $27.26M
Total Liabilities $141.79M $53.48M
Common Stock $5.00K $5.00K
Retained Earnings $-429.15M $-383.75M
Total Stockholders Equity $-8.10M $17.60M
Total Liabilities & Equity $133.69M $71.08M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-16.29M $-14.02M $-45.40M $-45.15M
Depreciation & Amortization - - $1.22M $1.27M
Stock-based Compensation - - $4.01M $4.92M
Change in Receivables - - $17.50M -
Change in Payables - - $-276.00K $-76.00K
Operating Cash Flow - - $-2.99M $-4.22M
Capital Expenditure - - $423.00K $30.00K
Investing Cash Flow - - $-423.00K $-30.00K
Debt Repayment - - - $3.33M
Financing Cash Flow - - $51.91M $20.99M
Net Change in Cash - - $48.49M $16.74M

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-Q filings.

Quarterly data represents single quarter results (Q1-Q4). Some items may show year-to-date values if quarterly breakdown is unavailable.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...